Test your knowledge of gMG


scroll to explore

scroll to explore icon

Why should managing gMG mean opening Pandora's box?

Management of generalized myasthenia gravis (gMG) is complicated. It often requires multiple approaches and monitoring, which can severely impact patients' quality of life.1-4

What does the burden of gMG really mean for patients? 


FcRn: a critical role

gMG is an autoimmune disorder of the musculoskeletal system caused by pathogenic immunoglobulin G (IgG) autoantibodies.1

Studies have explored targeting the neonatal Fc receptor (FcRn), as it plays a critical role in gMG by prolonging the half-life of IgG antibodies, including pathogenic antibodies.5,6

The FcRn Pathway

FcRn binds IgG antibodies, including pathogenic autoantibodies, rescuing them from lysosomal degradation and recycling them back into circulation.5


Managing gMG may unleash serious consequences3,4

Learn more about the implications for patients’ physical and psychological well-being.

References: 1. Gotterer L, Li Y. J Neurol Sci. 2016;369:294-302. doi:10.1016/j.jns.2016.08.057 2. Guo Y et al. Front Immunol. 2018;9:1299. doi:10.3389/fimmu.2018.01299 3. Liu D et al. Allergy Asthma Clin Immunol. 2013;9(1):30. doi:10.1186/1710-1492-9-30 4. Gilhus NE et al. Nat Rev Dis Primers. 2019;5(1):30. doi:10.1038/s41572-019-0079-y 5. Roopenian DC, Akilesh S. Nat Rev Immunol. 2007;7(9):715-725. doi:10.1038/nri2155 6. Ward ES, Ober RJ. Trends Pharmacol Sci. 2018;39(10):892-904. doi:10.1016/j.tips.2018.07.007